226 related articles for article (PubMed ID: 22266933)
21. Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis.
Lawlor RT; Veronese N; Pea A; Nottegar A; Smith L; Pilati C; Demurtas J; Fassan M; Cheng L; Luchini C
BMC Cancer; 2019 Mar; 19(1):232. PubMed ID: 30871494
[TBL] [Abstract][Full Text] [Related]
22. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
23. Alternative lengthening of telomeres frequently occurs in mismatch repair system-deficient gastric carcinoma.
Omori Y; Nakayama F; Li D; Kanemitsu K; Semba S; Ito A; Yokozaki H
Cancer Sci; 2009 Mar; 100(3):413-8. PubMed ID: 19154407
[TBL] [Abstract][Full Text] [Related]
24. TRF1 phosphorylation on T271 modulates telomerase-dependent telomere length maintenance as well as the formation of ALT-associated PML bodies.
Ho A; Wilson FR; Peragine SL; Jeyanthan K; Mitchell TR; Zhu XD
Sci Rep; 2016 Nov; 6():36913. PubMed ID: 27841304
[TBL] [Abstract][Full Text] [Related]
25. [The role of alternative lengthening of telomeres mechanisms in carcinogenesis and prospects for using an anti-telomerase drugs in malignant tumors treatment].
Grach AA
Tsitologiia; 2011; 53(10):759-71. PubMed ID: 22232932
[TBL] [Abstract][Full Text] [Related]
26. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
[TBL] [Abstract][Full Text] [Related]
27. Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study.
Abdulfatah E; Lordello L; Khurram M; Van de Vijver K; Alosh B; Bandyopadhyay S; Oliva E; Ali-Fehmi R
Int J Gynecol Pathol; 2019 May; 38(3):205-215. PubMed ID: 30958427
[TBL] [Abstract][Full Text] [Related]
28. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.
Henson JD; Reddel RR
FEBS Lett; 2010 Sep; 584(17):3800-11. PubMed ID: 20542034
[TBL] [Abstract][Full Text] [Related]
29. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.
McDonald KL; McDonnell J; Muntoni A; Henson JD; Hegi ME; von Deimling A; Wheeler HR; Cook RJ; Biggs MT; Little NS; Robinson BG; Reddel RR; Royds JA
J Neuropathol Exp Neurol; 2010 Jul; 69(7):729-36. PubMed ID: 20535033
[TBL] [Abstract][Full Text] [Related]
30. SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
Mangosh TL; Grabowska MM; Taylor DJ
Prostate; 2021 Nov; 81(15):1235-1251. PubMed ID: 34492133
[TBL] [Abstract][Full Text] [Related]
31. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.
Slatter T; Gifford-Garner J; Wiles A; Tan X; Chen YJ; MacFarlane M; Sullivan M; Royds J; Hung N
Am J Pathol; 2010 Dec; 177(6):2694-700. PubMed ID: 21037079
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison.
Kim HS; Han KH; Chung HH; Kim JW; Park NH; Song YS; Kang SB
Eur J Surg Oncol; 2010 Jul; 36(7):691-8. PubMed ID: 20570475
[TBL] [Abstract][Full Text] [Related]
33. Effect of silencing key proteins in telomerase mechanism and alternative lengthening of telomeres mechanism in laryngeal cancer cells.
Xu Y; Wang X; Chen SM; Chen C; Wang Y; Xiao BK; Tao ZZ
Am J Otolaryngol; 2016; 37(6):552-558. PubMed ID: 27726944
[TBL] [Abstract][Full Text] [Related]
34. Alternative Lengthening of Telomeres through Two Distinct Break-Induced Replication Pathways.
Zhang JM; Yadav T; Ouyang J; Lan L; Zou L
Cell Rep; 2019 Jan; 26(4):955-968.e3. PubMed ID: 30673617
[TBL] [Abstract][Full Text] [Related]
35. [Uterine sarcomas... or uterine carcinosarcomas?].
Leung F; Terzibachian JJ
J Gynecol Obstet Biol Reprod (Paris); 2010 Apr; 39(2):172. PubMed ID: 20079975
[No Abstract] [Full Text] [Related]
36. ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas.
Venturini L; Erdas R; Costa A; Gronchi A; Pilotti S; Zaffaroni N; Daidone M
J Pathol; 2008 Mar; 214(4):410-4. PubMed ID: 18085522
[TBL] [Abstract][Full Text] [Related]
37. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II.
Visnovsky J; Kudela E; Slavik P; Krkoska M; Buocik P; Szepe P; Danko J
Neuro Endocrinol Lett; 2015; 36(8):750-7. PubMed ID: 26921575
[TBL] [Abstract][Full Text] [Related]
38. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.
Arita S; Kikkawa F; Kajiyama H; Shibata K; Kawai M; Mizuno K; Nagasaka T; Ino K; Nomura S
Int J Gynecol Cancer; 2005; 15(2):329-36. PubMed ID: 15823121
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM
Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the predictivity of preoperative serum CA 125 in the differential diagnosis of uterine leiomyoma and uterine sarcoma in the Turkish female population.
Yilmaz N; Sahin I; Kilic S; Ozgu E; Gungor T; Bilge U
Eur J Gynaecol Oncol; 2009; 30(4):412-4. PubMed ID: 19761133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
